Two phase III trials that directly compared erlotinib and gefitinib were conducted in Asian patients; these two agents are comparably effective in previously treated EGFR mutation-positive NSCLC patients [18, 19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.